Should You Buy Myriad Genetics Inc (MYGN) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/30
Not a good buy right now. MYGN is in a clear bearish trend (bearish moving-average stack, weakening MACD) and the short-term statistical trend points to further downside over the next week/month. While the news flow is constructive (Precise MRD roadmap) and options positioning is extremely call-skewed, the stock is still trading weak into support and there are no Intellectia buy signals today—so for an impatient buyer looking to enter immediately, the risk/reward is not favorable at this moment.
Technical Analysis
Trend is bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating sustained downside momentum. MACD histogram is negative (-0.0235) and expanding negatively, suggesting selling pressure is still building rather than stabilizing. RSI_6 is ~27.3 (oversold/near-oversold), which can precede a bounce, but oversold readings can persist in downtrends. Key levels: price (~5.53 pre-market) is sitting just below S1 (5.554) with the next support at S2 (5.381). Overhead resistance starts at the pivot (5.835) then R1 (6.116). Near-term pattern-based probabilities also skew negative: +0.66% next day but -3.01% next week and -6.99% next month—consistent with a weak broader setup.
